Alkermes
disciplined capital allocation supports highest roi priorities develop next generation of pipeline candidates complete phase enabling activities initiate phase first in human study initiate phase study nominate candidate to the clinic oncology lead candidate generation advance lead candidate identification | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
30 of 144
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
December 2023
milestones achieved and upcoming potential catalysts | NeuroSense Therapeutics
Zurabio
SPAC
June 2022
we are planning to initiate two phase studies in | Zurabio
Xeris Biopharma
Investor Presentation
October 2022
phase study design | Xeris Biopharma
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io